PL371282A1 - Odżywczy preparat farmaceutyczny obejmujący polifenole i jego zastosowanie w leczeniu raka - Google Patents

Odżywczy preparat farmaceutyczny obejmujący polifenole i jego zastosowanie w leczeniu raka

Info

Publication number
PL371282A1
PL371282A1 PL03371282A PL37128203A PL371282A1 PL 371282 A1 PL371282 A1 PL 371282A1 PL 03371282 A PL03371282 A PL 03371282A PL 37128203 A PL37128203 A PL 37128203A PL 371282 A1 PL371282 A1 PL 371282A1
Authority
PL
Poland
Prior art keywords
cancer
treatment
polyphenols
pharmaceutical formulation
nutrient pharmaceutical
Prior art date
Application number
PL03371282A
Other languages
English (en)
Other versions
PL215159B1 (pl
Inventor
Matthias Rath
Shrirang Netke
Aleksandra Niedzwiecki
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23366808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL371282(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Matthias Rath filed Critical Matthias Rath
Publication of PL371282A1 publication Critical patent/PL371282A1/pl
Publication of PL215159B1 publication Critical patent/PL215159B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Przedmiotem wynalazku jest odżywczy preparat farmaceutyczny obejmujący kwas askorbinowy, L-lizynę, L-prolinę i co najmniej jeden związek polifenolowy wybrany z grupy obejmującej galusan epigalokatechiny, galusan epikatechiny, epigalokatechinę, epikatechinę, katechinę, oraz zastosowanie w leczeniu raka i innych nowotworów. Ujawniono farmaceutyczny preparat odżywczy EPICAN FORTE<sup>TM</sup> oraz sposób jego stosowania w zapobieganiu i leczeniu raka.
PL371282A 2002-01-11 2003-01-13 Odzywcza kompozycja farmaceutyczna uzyteczna w leczeniu raka oraz jej zastosowanie PL215159B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34814302P 2002-01-11 2002-01-11

Publications (2)

Publication Number Publication Date
PL371282A1 true PL371282A1 (pl) 2005-06-13
PL215159B1 PL215159B1 (pl) 2013-10-31

Family

ID=23366808

Family Applications (1)

Application Number Title Priority Date Filing Date
PL371282A PL215159B1 (pl) 2002-01-11 2003-01-13 Odzywcza kompozycja farmaceutyczna uzyteczna w leczeniu raka oraz jej zastosowanie

Country Status (26)

Country Link
US (2) US7041699B2 (pl)
EP (1) EP1465614B1 (pl)
JP (1) JP2005519055A (pl)
KR (1) KR20040073559A (pl)
CN (1) CN100377706C (pl)
AT (1) ATE382343T1 (pl)
AU (1) AU2003235762B2 (pl)
BR (1) BR0302672A (pl)
CA (1) CA2471932A1 (pl)
DE (1) DE60318387T2 (pl)
EE (1) EE200400032A (pl)
ES (1) ES2298519T3 (pl)
HR (1) HRP20040704A2 (pl)
HU (1) HUP0500498A3 (pl)
IL (1) IL162646A0 (pl)
LT (1) LT5240B (pl)
LV (1) LV13248B (pl)
MX (1) MXPA04006717A (pl)
NO (1) NO20033950L (pl)
NZ (1) NZ533737A (pl)
PL (1) PL215159B1 (pl)
RU (1) RU2301666C2 (pl)
UA (1) UA80692C2 (pl)
WO (1) WO2003057201A2 (pl)
YU (1) YU75003A (pl)
ZA (1) ZA200405075B (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034310B2 (en) * 2002-02-21 2015-05-19 Stephen B. Cantrell Interferon-statin combination cancer therapy
US7115283B2 (en) * 2003-05-06 2006-10-03 Access Business Group International Llc Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals
US20040253319A1 (en) * 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
KR20060069850A (ko) * 2003-09-05 2006-06-22 마티아스 라트 비타민 ｃ, 마그네슘, 녹차 추출물을 포함하는 심장혈관계질환을 억제하기 위한 약제 조성물
US8377904B2 (en) 2004-02-09 2013-02-19 Hill's Pet Nutrition, Inc. Composition and method for use in cartilage affecting conditions
US20050176674A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
KR100601080B1 (ko) * 2004-08-26 2006-07-19 가톨릭대학교 산학협력단 (-)-에피갈로카테킨 갈레이트를 유효성분으로 하는류마티스성 관절염 치료제
CA2596210C (en) 2005-02-03 2014-07-08 Topotarget Uk Limited Combination therapies using hdac inhibitors
EP1888061A1 (en) * 2005-04-11 2008-02-20 Matthias Rath Nutrient composition for treating sarcoma and prostate cancer
EP1874354A1 (en) 2005-04-11 2008-01-09 Rath, Matthias Nutrient composition comprising green tea polyphenols for treating osteosarcoma
US8835501B2 (en) * 2005-05-13 2014-09-16 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
EP1924257A4 (en) * 2005-07-26 2012-08-08 Mitsui Norin Kk STABILIZED 3-HYDROXYFLAVAN COMPOSITIONS AND METHOD THEREFOR
WO2007033356A2 (en) * 2005-09-14 2007-03-22 Mitsui Norin Co., Ltd Compositions and methods for green tea catechins for modification of detoxification enzymes
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
US20070212426A1 (en) * 2006-03-10 2007-09-13 Matthias Rath Composition and method of retarding viral activity and reducing viral replication
CA2689717C (en) 2006-06-16 2016-10-18 Summa Health System Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
GB0615781D0 (en) * 2006-08-09 2006-09-20 Coressence Ltd Prebiotic composition
US20080114054A1 (en) * 2006-11-14 2008-05-15 Rath Microbes Compositions and methods for reducing antimicrobial resistance of microbes
RU2328282C1 (ru) * 2007-04-23 2008-07-10 Закрытое акционерное общество "МираксБиоФарма" Фармацевтическая композиция для профилактики образования метастазов и повышения чувствительности (сенсибилизации) опухолей к химиотерапевтическим препаратам
US8617544B2 (en) * 2007-05-01 2013-12-31 Richard L. Kozlenko Compositions and methods for controlling lipid metabolism
GB0710536D0 (en) * 2007-06-01 2007-07-11 Veritron Ltd Plant extract and its therapeutic use
WO2009040517A2 (en) * 2007-09-25 2009-04-02 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
GB0725077D0 (en) * 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
EP2262493B1 (en) * 2008-03-07 2015-02-25 Topotarget A/S Methods of treatment employing prolonged continuous infusion of belinostat
RU2395281C2 (ru) * 2008-09-04 2010-07-27 Всеволод Иванович Киселев Фармацевтическая композиция для лечения диспластических процессов шейки матки
CA2742302C (en) 2008-11-04 2018-01-02 Vymedic, Llc Antiviral supplement formulations
US8677463B2 (en) * 2008-12-05 2014-03-18 At&T Intellectual Property I, Lp System and method for managing multiple sub accounts within a subcriber main account in a data distribution system
JP2009143928A (ja) * 2008-12-26 2009-07-02 Kyushu Univ ガロイルカテキン類の抗酸化活性の促進方法
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
CN101874822A (zh) 2009-04-27 2010-11-03 玫琳凯有限公司 植物性抗痤疮制剂
IT1397522B1 (it) * 2009-12-21 2013-01-16 Solartium Entpr Ltd Uso di una combinazione per il trattamento dell'osteoartrosi
GB201015784D0 (en) 2010-09-20 2010-10-27 Bionature E A Ltd Anti-cancer compounds
WO2013096485A1 (en) 2011-12-19 2013-06-27 Mary Kay Inc. Combination of plant extracts to improve skin tone
RU2522547C1 (ru) * 2012-11-12 2014-07-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Фармакологическая геропротекторная композиция и способ ее получения
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
US20160279043A1 (en) * 2013-03-18 2016-09-29 Dentalmed Pharm Holding Ltd. Combinations of n-acetyl cysteine derivatives and cranberry polyphenols in compositions and methods for preventing and treating periodontal diseases and peri-implatitis
BE1023772B9 (fr) * 2013-05-17 2017-08-02 Valore Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer
GB2520794A (en) * 2013-07-26 2015-06-03 Tata Memorial Ct Plant poly-phenol and copper (II) mediated degradation of DNA and RNA
IN2013MU01528A (pl) * 2013-07-26 2015-06-26 Tata Memorial Ct
US9849077B2 (en) 2014-03-10 2017-12-26 Mary Kay Inc. Skin lightening compositions
BE1022579A9 (fr) * 2014-11-10 2016-10-06 Valore Composition antimétastatique comprenant au moins un composé de type flavanol
CN105061533B (zh) * 2015-09-18 2018-02-09 福州大学 六甲氧基二氢黄酮‑鼠李糖基‑鼠李糖苷及其应用
CN106138036A (zh) * 2016-04-29 2016-11-23 陈西敬 抗坏血酸棕榈酸酯在制备抗肿瘤药物中的应用
CN110312439A (zh) 2016-10-03 2019-10-08 夏滉 用于增强癌症放射治疗的组合物和方法
JP7788129B2 (ja) 2017-06-13 2025-12-18 シャー，ホウン・サイモン 癌化学療法を増強するための組成物および方法
WO2018231937A2 (en) 2017-06-13 2018-12-20 Houn Simon Hsia Compositions and methods for enhancing cancer radiotherapy
US12029765B2 (en) 2017-06-13 2024-07-09 Houn Simon Hsia Compositions and methods for treating cancer
CN111529709A (zh) * 2020-06-03 2020-08-14 北京易思腾翻译服务有限公司 一种可用于体重控制且可逆转动脉粥样硬化的组合物
WO2022124386A1 (en) * 2020-12-07 2022-06-16 L' Oreal Composition comprising ascorbic acid and cyclic amino acid
IT202200010592A1 (it) * 2022-05-23 2023-11-23 Neilos S R L “Composizione nutraceutica o farmaceutica per l’infertilità maschile”

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4243363A1 (de) * 1992-12-21 1994-06-23 Ulrich Dr Med Kuebler Behandlungsverfahren für Hauttrockenheit
US5962517A (en) 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
EP0938897A1 (en) * 1997-12-26 1999-09-01 Japanese Foundation For Cancer Research Telomerase inhibitor
AT407821B (de) * 1998-03-24 2001-06-25 Franz Dr Stueckler Mittel auf der basis von naturstoffen
WO2000057875A1 (en) * 1999-03-30 2000-10-05 Purdue Research Foundation Compositions containing tea catechins as cancer specific proliferation inhibitors
CA2377414A1 (en) 1999-06-15 2000-12-21 John D. Potter Nutrient formulations for disease reduction, and related treatment and component screening methods
US6299925B1 (en) * 1999-06-29 2001-10-09 Xel Herbaceuticals, Inc. Effervescent green tea extract formulation
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
PT1195159E (pt) * 2000-10-09 2006-08-31 Rath Matthias Combinacao terapeutica de ascorbato com lisina e arginina para prevencao e tratamento do cancro
WO2007076492A2 (en) 2005-12-28 2007-07-05 Sandisk Corporation Methods and systems for writing non-volatile memories for increased endurance

Also Published As

Publication number Publication date
US20060142212A1 (en) 2006-06-29
AU2003235762B2 (en) 2008-10-02
CN1731989A (zh) 2006-02-08
ZA200405075B (en) 2006-07-26
LT5240B (lt) 2005-07-25
WO2003057201A3 (en) 2004-03-11
RU2004124384A (ru) 2005-04-20
HUP0500498A2 (hu) 2005-08-29
WO2003057201A2 (en) 2003-07-17
BR0302672A (pt) 2004-02-25
PL215159B1 (pl) 2013-10-31
HRP20040704A2 (en) 2004-10-31
HUP0500498A3 (en) 2013-01-28
LV13248B (en) 2005-06-20
ATE382343T1 (de) 2008-01-15
EP1465614A2 (en) 2004-10-13
JP2005519055A (ja) 2005-06-30
HK1086489A1 (zh) 2006-09-22
LT2004076A (en) 2005-02-25
DE60318387D1 (de) 2008-02-14
US20030170319A1 (en) 2003-09-11
MXPA04006717A (es) 2004-11-10
NO20033950D0 (no) 2003-09-05
EP1465614B1 (en) 2008-01-02
KR20040073559A (ko) 2004-08-19
ES2298519T3 (es) 2008-05-16
IL162646A0 (en) 2005-11-20
EE200400032A (et) 2004-04-15
UA80692C2 (en) 2007-10-25
DE60318387T2 (de) 2008-12-18
US7041699B2 (en) 2006-05-09
YU75003A (sh) 2006-08-17
CA2471932A1 (en) 2003-07-17
CN100377706C (zh) 2008-04-02
RU2301666C2 (ru) 2007-06-27
NZ533737A (en) 2006-02-24
AU2003235762A1 (en) 2003-07-24
NO20033950L (no) 2003-11-10

Similar Documents

Publication Publication Date Title
PL371282A1 (pl) Odżywczy preparat farmaceutyczny obejmujący polifenole i jego zastosowanie w leczeniu raka
KR100352030B1 (en) Gum composition for removing nicotine
WO2002022598A8 (en) Quinolinone derivatives as tyrosine kinase inhibitors
IL183953A0 (en) Method of reducing oxidant induced damage of a food product, a pharmaceutical, or stored blood
BR0315580A (pt) Derivados de metileno uréia
TW200637608A (en) Oral care composition containing extract of unoxidized camellia
WO2002081651A3 (en) Polyphenolics for enhancing endothelial cell-mediated fibrinolysis
WO2004009583A3 (en) Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor
DE60101486D1 (de) Verwendung von Polyaminosäurederivate als Konservierungsmittel
WO2005065639A3 (en) Novel pharmaceutical compositions
WO2003053960A3 (en) Quinline derivates and their use as mek inhibitors
TNSN08057A1 (en) Combinations comprising dmxaa for the treatment of cancer
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
EP1770090A4 (en) TEA-POLYPHENOL COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF
ATE430575T1 (de) Laspartomycin-derivate, sowie ihre herstellung und verwendung
WO2006032115A3 (en) Composition against cardiovascular diseases
WO2000000183A3 (en) Antioxidant, cytostatic and sustained energy composition which ameliorates the metabolic utilization of glucose comprising acetyl-l-carnitine and a catechin
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
WO2002078690A3 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
WO2006021888A3 (en) Dihydrofolate reductase inhibition by epigallocatechin gallate compounds
WO2004072037A8 (en) 2,3&#39;-bipyridines derivatives as selective cox-2 inhibitors
MX2021010491A (es) Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg).
BR0014751A (pt) Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto
WO2003095471A3 (en) Deoxycholic acid derivatives for the treatment of acute dysfunctions of portal and hepatic venous circulation
BRPI0520221A2 (pt) uso de uma composiÇço nutriente que compreende polifenàis de chÁ verde para tratamento de osteossarcoma

Legal Events

Date Code Title Description
RECP Rectifications of patent specification